Segment Reporting - Summary of Segment Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting [Abstract]
CDMO, CRO and Other Third-party Preclinical Studies, Clinical Trials and Consulting Costs	$ 25,108	$ 10,324
License fees, milestone payments, and annual maintenance fees related to acquired technologies	10	32,099
Internal research and development personnel expenses	5,244	2,490
Other research and development costs	391	129
General and administrative personnel expenses	4,447	1,940
Other general and administrative expenses	10,952	4,750
Interest expense	1,443	2,701
Other segment items	(4,157)	14,734
Net loss	$ (43,438)	$ (69,167)